P483 ABO blood group in monitoring response to infliximab treatment for Crohn's Disease
Q. Yu*, L. Wang, L. Li, S. Zhang, M. Chen
The First Affiliated Hospital of Sun Yat-Sen University, Gastroenterology, Guangzhou, China
The variation of ABO blood group is reported as a potential genetic risk factor for Crohn's disease (CD). However, its role in Chinese patients with CD was still unknown. The present study aimed to investigate the distribution of ABO blood group in Chinese patients with CD, and also to explore its impact on response to infliximab for CD.
Patients with CD were consecutively recruited in The First Affiliated Hospital, Sun Yat-sen University from between 2007 and 2014. Patients receiving infliximab therapy were under follow-up. ABO blood group antigen and Rh factor were characterized on peripheral blood samples. The distribution of ABO blood type in CD and its correlation with the response to infliximab were evaluated using unconditional logistic regression analysis.
Distribution of ABO group in patients with Crohn’s disease and the general population.
|Patients with Crohn’s disease, No. (%)||119 (40.6)||80 (27.3)||75 (25.6)||19 (6.5)|
|Chinese Han population, %||42||31||22||5|
Of 293 patients with CD, 119 patients were type O (40.6%), 80 type A (27.3%), 75 type B (25.6%), and 19 type AB (6.5%).
The odds ratio of CD in type O patients was 0.95 (95% CI, 0.55~ 1.68; P = 0.5) compared to all other blood types, while it was 0.82 (95% CI, 0.45~ 1.52; P = 0.32) in type A patients, and 1.21 (95% CI, 0.36~4.11; P = 0.5) in type AB patients. Overall 109 patients with CD received the treatment of infliximab in our centre. At 1 year (54w), 70 patients (66.0%) responded to induction therapy. Patients with CD with type AB blood (OR = 8.17, 95% CI, 1.530~ 43.641; P = 0.014) had an advantage to achieve mucosal healing, while patients with CD with type A blood appeared to had a high risk of loss response (OR = 0.372, 95% CI, 0.148~0.935; P = 0.036).
ABO blood type had no influence on the CD risk in Chinese population. Patients with type AB had a better response to infliximab whereas those with type A appeared to had a risk of loss response to infliximab for CD. Further study involving more patients would confirm this finding.